Supplementary tables

TAVI bioprosthesis type		No Conduction Abnormality (n = 38)	Conduction Abnormality (n = 20)	P value
Balloon-expandable		34 (89.5%)	16 (80%)	0.266
Self-expandable		3 (10.5%)	3 (15%)	
Mechanically-expandable		0 (0%)	1 (5%)	
Pre-TAVI balloon dilatation		10 (26.3%)	10 (50.0%)	0.071
Post-TAVI balloon dilatation		3 (8.1%)	3 (15%)	0.654
Valve size (mm)	**20**	1 (2.6%)	0 (0.0%)	0.112
	23	12 (31.6%)	5 (25.0%)	
	25	0 (0.0%)	3 (15.0%)	
	26	14 (36.8%)	4 (26.7%)	
	29	10 (26.3%)	8 (40.0%)	
	34	1 (2.6%)	0 (0.0.%)	
Valve size (mm)	**≤25**	13 (34.2%)	12 (40.0%)	N/A
	≥26	25 (65.8%)	20 (60.0%)	

Supplementary table 1: Comparison of TAVI bioprosthesis type between patients with and without CA

Variable	OR	95% CI for OR		P value
		Lower limit	Upper limit	
DLZ calcification adjacent to MS without low δMSID	4	0.299	53.468	0.295
low δMSID without DLZ calcification adjacent to MS	6	0.643	55.948	0.116
low δMSID & DLZ calcification adjacent to MS	36	3.193	405.897	0.004

Supplementary table 2: Univariate logistic regression comparing the association of different combinations of the risk factors for the outcome of post-TAVI conduction abnormality. Low δMSID defined as <1.25mm. MS- membranous septum, δMSID- difference between MS and implantation depth, DLZ- device landing zone.